Specifications: New Chemical Drug Substances and Products
2
sufficient to adequately describe specifications of higher molecular weight peptides
and polypeptides, and biotechnological/biological products. The ICH Guideline
Specifications: Test Procedures and Acceptance Criteria for
Biotechnological/Biological Products addresses guideline specifications, tests and
procedures for biotechnological/biological products. Radiopharmaceuticals, products
of fermentation, oligonucleotides, herbal products and crude products of animal or
plant origin are similarly not covered.
Guidance is provided with regard to acceptance criteria which should be established
for all new drug substances and new drug products, i.e. universal acceptance criteria,
and those that are considered specific to individual drug substances and / or dosage
forms. This guideline should not be considered all encompassing. New analytical
technologies, and modifications to existing technology, are continually being
developed. Such technologies should be used when justified.
Dosage forms addressed in this guideline include solid oral dosage forms, liquid oral
dosage forms, and parenterals (small and large volume). This is not meant to be an
all-inclusive list, or to limit the number of dosage forms to which this guideline
applies. The dosage forms presented serve as models, which may be applicable to
other dosage forms which have not been discussed. The extended application of the
concepts in this guideline to other dosage forms, e.g., to inhalation dosage forms
(powders, solutions, etc.), to topical formulations (creams, ointments, gels), and to
transdermal systems, is encouraged.
2. GENERAL CONCEPTS
The following concepts are important in the development and setting of harmonized
specifications. They are not universally applicable, but each should be considered in
particular circumstances. This guideline presents a brief definition of each concept
and an indication of the circumstances under which it may be applicable. Generally,
proposals to implement these concepts should be justified by the applicant and
approved by the appropriate regulatory authority before being put into effect.
2.1 Periodic or Skip Testing
Periodic or skip testing is the performance of specified tests at release on pre-selected
batches and / or at predetermined intervals, rather than on a batch-to-batch basis
with the understanding that those batches not being tested still must meet all
acceptance criteria established for that product. This represents a less than full
schedule of testing and should therefore be justified and presented to and approved
by the regulatory authority prior to implementation. This concept may be applicable
to, for example, residual solvents and microbiological testing, for solid oral dosage
forms. It is recognized that only limited data may be available at the time of
submission of an application (see section 2.5). This concept should therefore generally
be implemented post-approval. When tested, any failure to meet acceptance criteria
established for the periodic test should be handled by proper notification of the
appropriate regulatory authority(ies). If these data demonstrate a need to restore
routine testing, then batch by batch release testing should be reinstated.
2.2 Release vs. Shelf-life Acceptance Criteria
The concept of different acceptance criteria for release vs. shelf-life specifications
applies to drug products only; it pertains to the establishment of more restrictive
criteria for the release of a drug product than are applied to the shelf-life. Examples
where this may be applicable include assay and impurity (degradation product)
levels. In Japan and the United States, this concept may only be applicable to in-
house criteria, and not to the regulatory release criteria. Thus, in these regions, the